Neuland Laboratories Gestione
Gestione criteri di controllo 2/4
Neuland Laboratories Il CEO è Davuluri Rao, nominato in Aug2013, e ha un mandato di 11.25 anni. la retribuzione annua totale è ₹ 148.30M, composta da 16.3% di stipendio e 83.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 3.3% delle azioni della società, per un valore di ₹ 6.81B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.2 anni e 9.5 anni.
Informazioni chiave
Davuluri Rao
Amministratore delegato
₹148.3m
Compenso totale
| Percentuale dello stipendio del CEO | 16.3% |
| Mandato del CEO | 11.3yrs |
| Proprietà del CEO | 3.3% |
| Durata media del management | 4.2yrs |
| Durata media del Consiglio di amministrazione | 9.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14
Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up
Aug 22Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?
Aug 02Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00
Jul 12Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking
Jul 02Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's
Jun 19Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹3b |
| Jun 30 2024 | n/a | n/a | ₹3b |
| Mar 31 2024 | ₹148m | ₹24m | ₹3b |
| Dec 31 2023 | n/a | n/a | ₹3b |
| Sep 30 2023 | n/a | n/a | ₹3b |
| Jun 30 2023 | n/a | n/a | ₹2b |
| Mar 31 2023 | ₹58m | ₹20m | ₹2b |
| Dec 31 2022 | n/a | n/a | ₹1b |
| Sep 30 2022 | n/a | n/a | ₹831m |
| Jun 30 2022 | n/a | n/a | ₹651m |
| Mar 31 2022 | ₹30m | ₹15m | ₹638m |
| Dec 31 2021 | n/a | n/a | ₹593m |
| Sep 30 2021 | n/a | n/a | ₹731m |
| Jun 30 2021 | n/a | n/a | ₹742m |
| Mar 31 2021 | ₹34m | ₹11m | ₹806m |
| Dec 31 2020 | n/a | n/a | ₹540m |
| Sep 30 2020 | n/a | n/a | ₹384m |
| Jun 30 2020 | n/a | n/a | ₹257m |
| Mar 31 2020 | ₹22m | ₹10m | ₹162m |
| Dec 31 2019 | n/a | n/a | ₹321m |
| Sep 30 2019 | n/a | n/a | ₹257m |
| Jun 30 2019 | n/a | n/a | ₹216m |
| Mar 31 2019 | ₹13m | ₹10m | ₹164m |
| Mar 31 2018 | ₹5m | ₹3m | ₹121m |
Compensazione vs Mercato: La retribuzione totale di Davuluri ($USD 1.76M ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 610.84K ).
Compensazione vs guadagni: La retribuzione di Davuluri è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Davuluri Rao (49 yo)
11.3yrs
Mandato
₹148,300,000
Compensazione
Mr. Davuluri Sucheth Rao has been the Chief Executive Officer of Neuland Laboratories Limited since August 1, 2013, where Mr. Rao also served as its Chief Operating Officer. At Neuland, Sucheth has been re...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman & Chief Promoter and Member of Scientific Advisory Board | 40.8yrs | ₹148.50m | 26.37% ₹ 54.4b | |
| Vice Chairman & CEO | 11.3yrs | ₹148.30m | 3.3% ₹ 6.8b | |
| Vice Chairman & MD | 15.4yrs | ₹148.30m | 2.24% ₹ 4.6b | |
| Chief Financial Officer | 2yrs | Nessun dato | Nessun dato | |
| Chief Scientific Officer & Member of Scientific Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Company Secretary & Compliance Officer | 12.8yrs | Nessun dato | Nessun dato | |
| Senior VP of Global Head Sales & BD | no data | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Global API Sales | no data | Nessun dato | Nessun dato | |
| Chief Procurement Officer | no data | ₹6.81m | Nessun dato | |
| President of Business Development & Contract Manufacturing | no data | Nessun dato | Nessun dato | |
| Chief Quality Officer | less than a year | Nessun dato | Nessun dato |
4.2yrs
Durata media
54yo
Età media
Gestione esperta: Il team dirigenziale di NEULANDLAB è considerato esperto (durata media dell'incarico 4.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman & Chief Promoter and Member of Scientific Advisory Board | 40.8yrs | ₹148.50m | 26.37% ₹ 54.4b | |
| Vice Chairman & CEO | 21.3yrs | ₹148.30m | 3.3% ₹ 6.8b | |
| Vice Chairman & MD | 15.4yrs | ₹148.30m | 2.24% ₹ 4.6b | |
| Chief Scientific Officer & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 2yrs | ₹2.90m | 0.00062% ₹ 1.3m | |
| Non-Executive Independent Director | 5.8yrs | ₹3.24m | Nessun dato | |
| Independent Director | 1.3yrs | ₹2.82m | Nessun dato | |
| Non-Executive Director & Member of Scientific Advisory Board | 15.1yrs | ₹2.85m | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Non-Executive Independent Director | 9.5yrs | ₹3.16m | Nessun dato | |
| Independent Director | 1.3yrs | ₹2.82m | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato |
9.5yrs
Durata media
78yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NEULANDLAB sono considerati esperti (durata media dell'incarico 9.5 anni).